Filing Summary
Issuer and period: The supplied filing is a Form 10-Q for Repro Med Systems, Inc. (RMS), for the quarter ended August 31, 2016, covering the second quarter and first six months of fiscal 2017. This is the issuer name shown in the filing; it does not match the request metadata name, KORU Medical Systems, Inc.
Business Context and Financial Performance
RMS designs, manufactures, and markets medical devices, primarily infusion products for ambulatory care and portable suction products. Its principal product lines include the FREEDOM60 and FreedomEdge infusion systems, HIgH-Flo needle sets, and RES-Q-VAC suction systems.
| Metric | Three months ended Aug. 31, 2016 | Six months ended Aug. 31, 2016 |
|---|---|---|
| Net sales | $3.148 million | $6.138 million |
| Gross profit / margin | $1.955 million / 62.1% | $3.891 million / 63.4% |
| Operating expenses | $2.074 million | $4.380 million |
| Operating income (loss) | ($119,000) | ($489,000) |
| Net income (loss) | ($83,000) | ($316,000) |
| Net income (loss) per share, basic and diluted | ($0.00) | ($0.01) |
Cash flow and liquidity: For the six months, operating activities provided $84,000, investing activities used $199,000, and financing activities used $121,000, primarily for treasury-stock purchases. Cash and cash equivalents were $3.966 million at August 31, 2016, down from $4.202 million at February 29, 2016; certificates of deposit were an additional $261,000. Current assets were $7.012 million and current liabilities $1.414 million. The filing reports no interest expense or cash interest payments and does not identify interest-bearing debt.
Total liabilities were $1.540 million and stockholders’ equity was $6.803 million at August 31, 2016. Management said cash on hand and expected operating cash flows should fund operations, R&D, and capital expenditures for the next 12 months. This is management’s assessment, not formal financial guidance.
Material Changes Versus Prior Comparable Period
- Second-quarter sales declined 0.6% year over year. Domestic sales fell 7.1%, which management attributed mainly to a large clinical trial in the prior-year quarter; international sales rose 33.2%, supported by existing and new customers and RES-Q-VAC sales.
- First-half sales increased 5.9% year over year, with domestic sales up 5.7% and international sales up 6.5%, primarily from infusion products and new customers.
- First-half gross margin rose to 63.4% from 60.8%. Management cited lean-manufacturing improvements and the medical-device-tax moratorium, as well as higher sales.
- SG&A increased 38.9% for the quarter and 43.3% for the first half. Management cited professional and consulting fees for operations management and regulatory initiatives, sales-related payroll and international hiring, and website redesign work. R&D also increased, chiefly from added engineering resources and consulting.
- RMS moved from prior-year net income to a net loss in both the quarter and first half; management attributed the change mainly to higher SG&A.
- First-half operating cash flow fell to $84,000 from $704,000. The current period included a $316,000 net loss and higher prepaid expenses, partly offset by a $402,000 increase in accounts payable.
Outlook, Risks, Contingencies, and Unusual Items
- Management expects sales opportunities from new markets, therapies, countries, and FREEDOM60 enhancements. It highlighted a large home-care hospital system selecting FREEDOM60 for patients receiving antibiotic therapy. No quantified revenue or earnings forecast was provided.
- The FDA issued a warning letter on February 29, 2016, following a 2015 facility inspection. RMS submitted responses and was awaiting FDA review and an unannounced reinspection; manufacturing and distribution continued without interruption at the filing date.
- Patent and unfair-business-practice litigation with EMED remains unresolved. The court had pending motions concerning RMS labeling and a requested injunction to prevent sales of FREEDOM60, as well as a separate motion seeking to bar sales of three products in California. A related Texas patent case was stayed pending USPTO review. RMS warned that adverse outcomes could materially affect its business, results, financial condition, and cash flows.
- RMS reported a first-half $920,000 of professional fees related to litigation and regulatory matters. Its non-GAAP normalized EBITDA was $586,000 and normalized net income $292,000 for the first half, versus GAAP net loss of $316,000; these measures exclude specified professional fees and associated tax effects and should not replace GAAP results.
- The board increased the share repurchase authorization to 2.0 million shares. By August 31, RMS reported 350,456 shares repurchased under the program at an average $0.45 per share; it also repurchased 96,542 shares from a former interim COO under a termination agreement. The filing reports $121,000 of cash used for treasury-stock purchases.
- The 2015 Stock Option Plan was amended to authorize up to 4.0 million shares and approved by shareholders on September 6, 2016. At August 31, 965,000 options were outstanding; unrecognized compensation cost was approximately $0.1 million.
- Other disclosed risks include competition, reimbursement and regulation of home health care, product acceptance, product development, access to capital, and dependence on key personnel. Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Confirm the issuer identity: the source filing names Repro Med Systems, Inc., while the request metadata names KORU Medical Systems, Inc.
- Track the FDA’s review, required remediation, and reinspection status, and whether manufacturing or distribution is affected.
- Monitor the EMED litigation, especially the pending injunction requests and possible effects on FREEDOM60 or other product sales.
- Assess whether sales growth and gross-margin gains can offset elevated SG&A, and whether operating cash flow improves from the first-half level.
- Reconcile cash, cash equivalents, and certificates of deposit when evaluating liquidity; the MD&A describes cash as $4.2 million, while the balance sheet reports $3.966 million in cash and $261,000 in certificates of deposit.
- Evaluate the cash and dilution implications of ongoing repurchases, director stock compensation, and the expanded stock-option plan; distinguish management’s adjusted non-GAAP measures from GAAP performance.